FOXO4-DRI

Overview

FOXO4-DRI is a synthetic peptide from the foundational 2017 Cell paper (Baar et al., from Erasmus University Medical Center) that helped launch broad interest in "senolytics" — compounds designed to selectively eliminate senescent cells, the aged, non-dividing cells that accumulate with age and secrete inflammatory signals (the "senescence-associated secretory phenotype," or SASP). It's a "D-retro-inverso" peptide: built from mirror-image D-amino acids in reversed sequence, a design specifically intended to resist normal enzymatic degradation while preserving its target-binding shape.

Proposed Mechanism of Action

FOXO4-DRI is designed to disrupt the interaction between FOXO4 and p53, two proteins that senescent cells rely on to suppress apoptosis (programmed cell death) and survive despite cellular damage. By blocking this interaction, FOXO4-DRI is proposed to selectively push senescent cells toward apoptosis while sparing healthy, non-senescent cells.

Research Context

The foundational study demonstrated FOXO4-DRI's effects across multiple models: it induced apoptosis specifically in senescent (not healthy) cells in vitro, and in aged and chemotherapy-damaged mice, treatment restored measures of fitness including fur density, renal function, and running endurance. Follow-up research (referenced in our broader search but not independently verified for this profile) has since extended findings to specific tissue contexts, including vascular aging, senescent Leydig cells and age-related testosterone decline, and pulmonary fibrosis models.

Limitations of the Current Evidence

• All of the evidence we verified here is preclinical — mouse and cell-culture studies. FOXO4-DRI has not been through human clinical trials, and is not approved for any use.
• Senescent cell elimination is a genuinely active, still-maturing research field; the foundational 2017 paper was influential but represents an early stage of a research program, not a settled, replicated therapeutic protocol.
• "D-retro-inverso" peptides are specifically engineered to resist normal proteolytic breakdown — a property that changes their pharmacokinetics in ways not shared by most other peptides discussed on this site, worth keeping in mind if comparing dosing intuitions across compounds.